Abstract B005: Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board

作者
Maud T Kamal,Kimya Rahmani Narj Abadi,R. Sanchez,Célia Dupain,Isabelle Guillou,Grégoire Marret,Zahra Castel Ajgal,Marie Paule Sablin,Cindy Neuzillet,Amani Asnacios Lecerf,Édith Borcoman,S. Hescot,Florence Coussy,Manuel Jorge Rodrigues,Nicolas Girard,Sarah Watson,Julien Masliah‐Planchon,Jennifer Wong,Abderaouf Hamza,Céline Callens
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): B005-B005
标识
DOI:10.1158/1535-7163.targ-23-b005
摘要

Abstract Introduction: The European Society of Medical Oncology Scale of Actionability of molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GA) of advanced cancer patients. We aimed to analyze the impact of matched therapies administered based on GAs identified through Institut Curie Molecular Tumor Board (MTB) between January 2018 and December 2022, according to ESCAT classification. Patients and methods: Between 2018 and 2022, 1,445 patients were discussed at Institut Curie MTB. Inclusion criteria were pre-defined as: adult patients (>18 years) with advanced or rare cancers. Tumors characteristics, pathological and genomic analyses, MTB conclusions, and follow-up after MTB were collected. Molecular analyses included a custom in-house NGS panel of 571 genes (DRAGON) and targeted RNAseq (ARCHER FusionPlex® CTL panel) or WGS, WES and RNAseq performed on the SEQOIA platform as part of the French Genomic Medecine Plan 2025. Clinical endpoints were Objective Response Rates (ORR), Progression-Free Survival (PFS) and Overall Survival (OS). ORR, PFS and OS of the population of patients receiving matched therapies were analyzed according to ESCAT Tiers. Results: Median patients age was 59 in the global MTB population (range=18-95; n=1,445) and mostly females (968/1,445; 67%). Most frequent tumors were from breast (20%), head and neck (10%), pancreas (10%), colon/rectum (9%), ovary (7%), lung (7%), soft tissue (7%), uterus (6%) or uveal melanoma (5%). Of the 1,445 patients, 995 had a tumor molecular profiling (69%). Actionable GAs were found in 576/995 (58%) of patients and 211/995 (21%) patients were oriented towards matched therapy. Simultaneously, some patients have also been referred to a genetic consultation when GA may correspond to a known predisposition gene. Among the 211 patients oriented towards matched therapy and after clinical evaluation for each patient, 101/211 (47%) representing 101/995 (10%) of the total patients actually received a matched therapy according to 102 actionable GAs identified through MTB analysis. The main actionable GAs detected were found in PIK3CA (12%), ERBB2 (11%), BRCA2 (6%) and FGFR3 (5%) genes. Among these, 40/102 GAs (40%) were classified as tier I, 4 (4%) as tier II, 35 (35%) as tier III, 18 (18%) as tier IV and 5 (5%) as tier X according to ESCAT. For those patients, PFS and OS were significantly improved when treatment was administered based on ESCAT tiers I/II (p=0.0486 for PFS, and p=0.0224 for OS). Worst clinical outcomes were observed for hypothetical targets classified as Tiers III and IV. Conclusions: High throughput screening was feasible for a majority of patients enrolled in the MTB. Among the patients screened, actionable GAs are identified in 58% of the patients. Yet 21% were oriented to matched therapy. Finally, 10% of patients were eventually treated with matched therapy, with a favorable outcome observed in patients with ESCAT Tiers I/II. Citation Format: Maud Kamal, Kimya Rahmani Narj Abadi, Raphaël Sanchez, Célia Dupain, Isabelle Guillou, Grégoire Marret, Zahra Castel Ajgal, Marie Paule Sablin, Cindy Neuzillet, Amani Asnacios Lecerf, Edith Borcoman, Ségolène Hescot, Florence Coussy, Manuel Rodrigues, Nicolas Girard, Sarah Watson, Julien Masliah Planchon, Jennifer Wong, Abderaouf Hamza, Celine Callens, Olfa Trabelsi Grati, Samia Melaabi, Keltouma Driouch, Emmanuelle Mouret-Fourme, Chrystelle Colas, Samantha Antonio, Odette Mariani, Michèle Nijnikoff, Anne Vincent-Salomon, Yves Allory, Ivan Bieche, Christophe Le Tourneau. Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B005.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
fiveby完成签到 ,获得积分10
1秒前
jean发布了新的文献求助10
2秒前
彭于晏的应助被思恩Shen采纳,获得10
2秒前
Lars发布了新的文献求助10
2秒前
fanfan完成签到,获得积分10
3秒前
李妍发布了新的文献求助80
3秒前
小古完成签到,获得积分10
4秒前
PEACE发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
8秒前
fishss完成签到,获得积分0
9秒前
MADAO发布了新的文献求助30
9秒前
Nidhogg完成签到,获得积分20
10秒前
852的应助被俭朴钢铁侠采纳,获得10
10秒前
那地方完成签到,获得积分0
10秒前
小马甲的应助被等风归采纳,获得10
10秒前
小蜜蜂完成签到,获得积分10
10秒前
在水一方的应助被喝口可乐采纳,获得30
10秒前
LW3366发布了新的文献求助10
11秒前
马亚斌发布了新的文献求助10
11秒前
秋风的应助被芒果彩虹猪采纳,获得20
12秒前
GPTea的应助被jean采纳,获得20
12秒前
applennad完成签到,获得积分10
12秒前
13秒前
14秒前
14秒前
努力搬砖的小胡完成签到,获得积分10
15秒前
稳重的元瑶完成签到,获得积分10
15秒前
马亚斌完成签到,获得积分20
16秒前
瓦松完成签到,获得积分20
17秒前
等风归完成签到,获得积分10
17秒前
云朝完成签到,获得积分10
18秒前
19秒前
19秒前
ZeKaWa的应助被liu采纳,获得10
19秒前
PEACE完成签到 ,获得积分20
19秒前
儒雅黑猫完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621